| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1007277717 |
| P356 | DOI | 10.2165/00003495-200262001-00007 |
| P698 | PubMed publication ID | 12479597 |
| P2093 | author name string | Jeffrey Crawford | |
| P2860 | cites work | Filgrastim (r-metHuG-CSF): the first 10 years. | Q34398810 |
| The uses and properties of PEG-linked proteins | Q35571427 | ||
| 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America | Q38556043 | ||
| Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy | Q40725458 | ||
| Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer | Q40746556 | ||
| Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01 (PEG-r-metHu G-CSF). | Q43670911 | ||
| Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer | Q43872776 | ||
| Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans | Q71249390 | ||
| Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma | Q72174351 | ||
| Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up | Q72596355 | ||
| 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel | Q73080412 | ||
| A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans | Q73370268 | ||
| Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy | Q73993174 | ||
| Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B | Q77156165 | ||
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 89-98 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia | |
| P478 | volume | 62 Suppl 1 |
| Q37185734 | A flow cytometric method for determination of the blood neutrophil fraction in rats |
| Q45845662 | A pharmacokinetic model of filgrastim and pegfilgrastim application in normal mice and those with cyclophosphamide-induced granulocytopaenia |
| Q37626772 | Colony-stimulating factors for febrile neutropenia during cancer therapy |
| Q36618400 | Granulocyte and granulocyte macrophage colony-stimulating factors as therapy in human and veterinary medicine |
| Q36677460 | Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia |
| Q36427261 | Pharmacokinetic and -dynamic modelling of G-CSF derivatives in humans |
| Q101137934 | Preparation, Characterization and Pharmacokinetic study of N-Terminal PEGylated D-form Antimicrobial Peptide OM19r-8 |
| Q35200824 | Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy |
| Q80975625 | Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma |
Search more.